MiMedx prices $34m public offering
This article was originally published in Clinica
Executive Summary
Marietta, Georgia-based MiMedx, which develops regenerative biomaterials and bioimplants processed from human amniotic membrane, has priced a $34m underwritten public offering to raise funds for R&D projects, approval applications and "future acquisitions of complementary businesses."